Department of Breast Surgery, Baotou Cancer Hospital, No.18 Tuanjie Street, Qingshan District, Baotou, 014030, Inner Mongolia, China.
Department of Operating Room, Baotou Cancer Hospital, Baotou, 014030, Inner Mongolia, China.
World J Surg Oncol. 2023 Mar 29;21(1):116. doi: 10.1186/s12957-023-02998-8.
To analyze the factors related to the efficacy of neoadjuvant therapy for breast cancer and find appropriate evaluation methods for evaluating the efficacy of neoadjuvant therapy METHODS: A total of 143 patients with breast cancer treated by neoadjuvant chemotherapy at Baotou Cancer Hospital were retrospectively analyzed. The chemotherapy regimen was mainly paclitaxel combined with carboplatin for 1 week, docetaxel combined with carboplatin for 3 weeks, and was replaced with epirubicin combined with cyclophosphamide after evaluation of disease progression. All HER2-positive patients were treated with simultaneous targeted therapy, including trastuzumab single-target therapy and trastuzumab combined with pertuzumab double-target therapy. Combined with physical examination, color Doppler ultrasound, and magnetic resonance imaging (MRI), a systematic evaluation system was initially established-the "triple evaluation method." A baseline evaluation was conducted before treatment. The efficacy was evaluated by physical examination and color Doppler every cycle, and the efficacy was evaluated by physical examination, color Doppler, and MRI every two cycles.
The increase in ultrasonic blood flow after treatment could affect the efficacy of monitoring. The presence of two preoperative time-signal intensity curves is a therapeutically effective protective factor for inflow. The triple evaluation determined by physical examination, color Doppler ultrasound, and MRI in determining clinical efficacy is consistent with the effectiveness of the pathological gold standard.
The therapeutic effect of neoadjuvant therapy can be better evaluated by combining clinical physical examination, color ultrasound, and nuclear magnetic resonance evaluation. The three methods complement each other to avoid the insufficient evaluation of a single method, which is convenient for most prefecty-level hospitals. Additionally, this method is simple, feasible, and suitable for promotion.
分析乳腺癌新辅助化疗疗效的相关因素,寻找合适的评价方法来评估新辅助化疗的疗效。
回顾性分析包头市肿瘤医院 143 例接受新辅助化疗的乳腺癌患者。化疗方案主要为紫杉醇联合卡铂 1 周,多西他赛联合卡铂 3 周,病情进展后评估更换表柔比星联合环磷酰胺。所有 HER2 阳性患者均同时进行靶向治疗,包括曲妥珠单抗单靶治疗和曲妥珠单抗联合帕妥珠单抗双靶治疗。结合体格检查、彩色多普勒超声和磁共振成像(MRI),初步建立了一个系统的评价体系——“三联评估法”。治疗前进行基线评估,每周期通过体格检查和彩色多普勒进行疗效评估,每 2 周期通过体格检查、彩色多普勒和 MRI 进行疗效评估。
治疗后超声血流增加可影响监测疗效,术前存在 2 条时间-信号强度曲线是流入有效的治疗保护因素。体格检查、彩色多普勒超声和 MRI 三联评估法判断临床疗效与病理金标准的有效性一致。
将临床体格检查、彩色超声和磁共振评估相结合,可以更好地评估新辅助治疗的疗效。三种方法相互补充,避免了单一方法的评价不足,方便了大多数地市级医院。此外,该方法简单、可行,适合推广。